+

WO2002069944A3 - Novel medicament compositions based on anticholinergics and on nk1 receptor antagonists - Google Patents

Novel medicament compositions based on anticholinergics and on nk1 receptor antagonists Download PDF

Info

Publication number
WO2002069944A3
WO2002069944A3 PCT/EP2002/001987 EP0201987W WO02069944A3 WO 2002069944 A3 WO2002069944 A3 WO 2002069944A3 EP 0201987 W EP0201987 W EP 0201987W WO 02069944 A3 WO02069944 A3 WO 02069944A3
Authority
WO
WIPO (PCT)
Prior art keywords
anticholinergics
receptor antagonists
compositions based
medicament compositions
novel medicament
Prior art date
Application number
PCT/EP2002/001987
Other languages
German (de)
French (fr)
Other versions
WO2002069944A2 (en
Inventor
Christopher John Montagu Meade
Michel Pairet
Michael Paul Pieper
Original Assignee
Boehringer Ingelheim Pharma
Christopher John Montagu Meade
Michel Pairet
Michael Paul Pieper
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to MXPA03008051A priority Critical patent/MXPA03008051A/en
Application filed by Boehringer Ingelheim Pharma, Christopher John Montagu Meade, Michel Pairet, Michael Paul Pieper filed Critical Boehringer Ingelheim Pharma
Priority to JP2002569121A priority patent/JP2004519484A/en
Priority to EP02719915A priority patent/EP1370293A2/en
Priority to CA002439915A priority patent/CA2439915A1/en
Priority to AU2002251010A priority patent/AU2002251010A1/en
Publication of WO2002069944A2 publication Critical patent/WO2002069944A2/en
Publication of WO2002069944A3 publication Critical patent/WO2002069944A3/en
Priority to AU2006202723A priority patent/AU2006202723B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention relates to novel medicament compositions based on anticholinergics and on NK1 receptor antagonists, to methods for the production thereof, and to their use in the treatment of respiratory tract diseases.
PCT/EP2002/001987 2001-02-23 2002-02-26 Novel medicament compositions based on anticholinergics and on nk1 receptor antagonists WO2002069944A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
MXPA03008051A MXPA03008051A (en) 2001-03-08 2002-02-22 Novel medicament compositions based on anticholinergics and on nk1 receptor antagonists.
JP2002569121A JP2004519484A (en) 2001-03-08 2002-02-26 Novel pharmaceutical compositions based on anticholinergic drugs and NK1-receptor antagonists
EP02719915A EP1370293A2 (en) 2001-03-08 2002-02-26 Novel medicament compositions based on anticholinergics and on nk1 receptor antagonists
CA002439915A CA2439915A1 (en) 2001-03-08 2002-02-26 New pharmaceutical compositions based on anticholinergics and nk1-receptor antagonists
AU2002251010A AU2002251010A1 (en) 2001-03-08 2002-02-26 Novel medicament compositions based on anticholinergics and on nk1 receptor antagonists
AU2006202723A AU2006202723B2 (en) 2001-02-23 2006-06-26 Novel genes encoding novel proteolytic enzymes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10111058.8 2001-03-08
DE10111058A DE10111058A1 (en) 2001-03-08 2001-03-08 New drug compositions based on anticholinergics and NK¶1¶ receptor antagonists

Publications (2)

Publication Number Publication Date
WO2002069944A2 WO2002069944A2 (en) 2002-09-12
WO2002069944A3 true WO2002069944A3 (en) 2003-10-02

Family

ID=7676673

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/001987 WO2002069944A2 (en) 2001-02-23 2002-02-26 Novel medicament compositions based on anticholinergics and on nk1 receptor antagonists

Country Status (7)

Country Link
EP (1) EP1370293A2 (en)
JP (1) JP2004519484A (en)
AU (1) AU2002251010A1 (en)
CA (1) CA2439915A1 (en)
DE (1) DE10111058A1 (en)
MX (1) MXPA03008051A (en)
WO (1) WO2002069944A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7244415B2 (en) 2002-03-28 2007-07-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg HFA suspension formulations of an anhydrate
DE10214264A1 (en) * 2002-03-28 2003-10-16 Boehringer Ingelheim Pharma HFA suspension formulations of an anhydrate
DE10230750A1 (en) * 2002-07-09 2004-01-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg New drug compositions based on new anticholonergics and NK1 receptor antagonists
WO2005004875A1 (en) * 2003-07-14 2005-01-20 Sankyo Company, Limited Medicinal composition for pulmonary administration
JP2006160639A (en) * 2004-12-06 2006-06-22 Sankyo Co Ltd Combined use of neurokinin receptor antagonist and anti-cholin agent
ITRM20120331A1 (en) * 2012-07-12 2014-01-13 Guidotti & C Spa Labor LIQUID ORAL PEDIATRIC COMPOSITIONS CONTAINING NEPADUTANT.
WO2015111627A1 (en) * 2014-01-21 2015-07-30 味の素株式会社 Sugar amino acid and use thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0581167A1 (en) * 1992-07-27 1994-02-02 Kyorin Pharmaceutical Co., Ltd. Novel arylglycinamide derivatives and preparative processes therefor and their use for treatment of dysuria
US5545617A (en) * 1993-11-12 1996-08-13 The Schepens Eye Research Institute, Inc. Therapeutic regulation of abnormal conjunctival goblet cell mucous secretion
WO1997032865A1 (en) * 1996-03-06 1997-09-12 Boehringer Ingelheim Pharma Kg Novel aryl glycinamide derivatives, method of producing said derivatives and pharmaceutical compositions containing these compounds
WO1999064010A1 (en) * 1998-06-11 1999-12-16 Merck Sharp & Dohme Limited Use of a nk-1 receptor antagonist for treating psychiatric disorders
US6124319A (en) * 1997-01-21 2000-09-26 Merck & Co., Inc. 3,3-disubstituted piperidines as modulators of chemokine receptor activity

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0581167A1 (en) * 1992-07-27 1994-02-02 Kyorin Pharmaceutical Co., Ltd. Novel arylglycinamide derivatives and preparative processes therefor and their use for treatment of dysuria
US5545617A (en) * 1993-11-12 1996-08-13 The Schepens Eye Research Institute, Inc. Therapeutic regulation of abnormal conjunctival goblet cell mucous secretion
WO1997032865A1 (en) * 1996-03-06 1997-09-12 Boehringer Ingelheim Pharma Kg Novel aryl glycinamide derivatives, method of producing said derivatives and pharmaceutical compositions containing these compounds
US6124319A (en) * 1997-01-21 2000-09-26 Merck & Co., Inc. 3,3-disubstituted piperidines as modulators of chemokine receptor activity
WO1999064010A1 (en) * 1998-06-11 1999-12-16 Merck Sharp & Dohme Limited Use of a nk-1 receptor antagonist for treating psychiatric disorders

Also Published As

Publication number Publication date
WO2002069944A2 (en) 2002-09-12
AU2002251010A1 (en) 2002-09-19
MXPA03008051A (en) 2003-12-04
CA2439915A1 (en) 2002-09-12
EP1370293A2 (en) 2003-12-17
DE10111058A1 (en) 2002-09-12
JP2004519484A (en) 2004-07-02

Similar Documents

Publication Publication Date Title
SG158731A1 (en) Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics
WO2003084539A3 (en) New pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors
WO2002069945A3 (en) Novel medicament compositions on the basis of anticholinergics and pde iv inhibitors
WO2002047668A3 (en) Novel medicament compositions based on anticholinesterase drugs and on ciclesonides
SG167657A1 (en) Novel medicament compositions based on tiotropium salts and on salmeterol salts
CA2436540A1 (en) Pharmaceutical compositions based on anticholinergics and corticosteroids
WO2004071529A3 (en) Uses of anti-insulin-like growth factor i receptor antibodies
IL164108A (en) Quinoline derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of medicaments for the treatment of cns and other disorders
WO2003000241A3 (en) Novel pharmaceutical compositions based on anticholinergic agents, corticosteroids and betamimetic agents, for the treatment of inflammatory and/or obstructive respiratory tract diseases
WO2003096990A3 (en) Protein cages for the delivery of medical imaging and therapy
AU2003289888A1 (en) Benzoxazinone derivatives, preparation thereof and uses in the treatment of cns and other disorders
WO2002088100A3 (en) Deuterated 3-piperidinopropiophenone and medicaments containing said compounds
TW200621765A (en) Substituted phenylaminothiazoles and their use
WO2003087049A3 (en) Pharmaceutical combinations containing heterocyclic compounds and a novel anticholinergic agent
WO2003039539A3 (en) Use of endothelin receptor antagonists in the treatment of tumour diseases
EP1262197A3 (en) Combination treatment for sleep disorders including sleep apnea
WO2002069944A3 (en) Novel medicament compositions based on anticholinergics and on nk1 receptor antagonists
TWI347845B (en) Pharmaceutical compositions,combinations,and kits for the treatment of respiratory diseases and use of the same
WO2005063757A3 (en) Novel crystalline forms of temozolomide
WO2002074034A3 (en) Novel medicament compositions based on anticholinergic agents and endothelin antagonists
WO2000076500A8 (en) Compound for use as a medicament for treatment of disorders involving bronchocontraction
AU2003245989A1 (en) Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases
WO2005094798A3 (en) Pharmaceutical compositions based on anticholinergics and ccr2 receptor antagonists
WO2004105759A3 (en) Novel long-acting medicament combinations comprising an anticholinergic agent and a $g(b)2-adrenoreceptor antagonist for the treatment of respiratory tract diseases
CA2436537A1 (en) Pharmaceutical compositions comprising tiotropium salts and antihistamines

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002719915

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2439915

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/008051

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2002569121

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2002719915

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载